Today: 3 July 2026
Browse Category

LSE:AZN.L 8 December 2025 - 31 January 2026

AstraZeneca share price: $18.5 billion China obesity-drug deal puts AZN stock in focus for Monday

AstraZeneca share price: $18.5 billion China obesity-drug deal puts AZN stock in focus for Monday

LONDON, Jan 31, 2026, 19:07 GMT — Market closed AstraZeneca PLC shares climbed on Friday after the drugmaker struck a deal to license obesity and weight management drug candidates from CSPC Pharmaceutical Group, in a pact valued at up to $18.5 billion. CSPC revealed AstraZeneca would pay $1.2 billion upfront, with an additional $17.3 billion contingent on meeting milestones. Tony Ren of Macquarie Capital described the move as a “buy the rumour, sell the news” play, after CSPC’s shares dropped nearly 12% in Hong Kong.
31 January 2026
··
Best UK Stocks to Buy Today (8 December 2025): 7 FTSE 100 Ideas for a Potential Rate‑Cut Era

Best UK Stocks to Buy Today (8 December 2025): 7 FTSE 100 Ideas for a Potential Rate‑Cut Era

Updated: 8 December 2025 – UK market close The UK stock market has quietly turned into one of 2025’s star performers. The FTSE 100 is trading around 9,660 and has delivered a total return of roughly 20–23% year‑to‑date, one of its best years since the aftermath of the financial crisis.Investors Chronicle+2Wealth DFM+2
8 December 2025
·········

Stock Market Today

  • Arm Holdings posts 20% revenue jump, powered by Q4 licensing gains
    July 3, 2026, 12:05 PM EDT. Arm Holdings said Q4 revenue rose 20% from a year ago to $1.49 billion, as licensing and other revenue climbed 29% to $819 million. The company is seeing licensing drive growth with strong demand for its processor designs for AI, cloud and smartphones. Royalty revenue was up 11% to $671 million, as more customers adopt Armv9 and Arm Compute Subsystems. Unlike rivals NVIDIA and AMD, Arm collects both licensing fees and ongoing royalties, giving the company a mix of upfront and recurring revenue as AI and advanced computing markets grow.
Go toTop